<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37809067</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Extracellular vesicles as biomarkers for AIDS-associated non-Hodgkin lymphoma risk.</ArticleTitle><Pagination><StartPage>1259007</StartPage><MedlinePgn>1259007</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1259007</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1259007</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Extracellular vesicles are membrane-bound structures secreted into the extracellular milieu by cells and can carry bioactive molecules. There is emerging evidence suggesting that EVs play a role in the diagnosis, treatment, and prognosis of certain cancers. In this study, we investigate the association of EVs bearing PD-L1 and molecules important in B-cell activation and differentiation with AIDS-NHL risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">EVs were isolated from archived serum collected prior to the diagnosis of AIDS-NHL in cases (N = 51) and matched HIV+ controls (N = 52) who were men enrolled in the Los Angeles site of the MACS/WIHS Combined Cohort Study (MWCCS). Serum specimens of AIDS-NHL cases were collected at a mean time of 1.25 years (range of 2 to 36 months) prior to an AIDS-NHL diagnosis. The expression of PD-L1 and other molecules on EVs (CD40, CD40L, TNF-RII, IL-6R&#x3b1;, B7-H3, ICAM-1, and FasL) were quantified by Luminex multiplex assay.</AbstractText><AbstractText Label="RESULTS AND DISCUSSION" NlmCategory="UNASSIGNED">We observed significantly higher levels of EVs bearing PD-L1, CD40, TNF-RII and/or IL-6R&#x3b1; in AIDS-NHL cases compared with controls. Using multivariate conditional logistic regression models adjusted for age and CD4<sup>+</sup> T-cell count, we found that EVs bearing PD-L1 (OR = 1.93; 95% CI: 1.10 - 3.38), CD40 (OR = 1.97, 95% CI: 1.09 - 3.58), TNF-RII (OR = 5.06; 95% CI: 1.99 - 12.85) and/or IL-6R&#x3b1; (OR = 4.67; 95% CI: 1.40 - 15.53) were significantly and positively associated with AIDS-NHL risk. In addition, EVs bearing these molecules were significantly and positively associated with non-CNS lymphoma: PD-L1 (OR = 1.94; 95% CI: 1.01 - 3.72); CD40 (OR = 2.66; 95% CI: 1.12 - 6.35); TNF-RII (OR = 9.64; 95% CI: 2.52 - 36.86); IL-6R&#x3b1; (OR = 8.34; 95% CI: 1.73 - 40.15). These findings suggest that EVs bearing PD-L1, CD40, TNF-RII and/or IL-6R&#x3b1; could serve as biomarkers for the early detection of NHL in PLWH.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Mart&#xed;nez, Magpantay, Guo, Hegde, Detels, Hussain and Epeldegui.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magpantay</LastName><ForeName>Larry I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hegde</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Detels</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Shehnaz K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, School of Medicine and Comprehensive Cancer Center, University of California, Davis, Davis, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epeldegui</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AIDS-NHL</Keyword><Keyword MajorTopicYN="N">CD40</Keyword><Keyword MajorTopicYN="N">IL-6R&#x3b1;</Keyword><Keyword MajorTopicYN="N">PD-L1</Keyword><Keyword MajorTopicYN="N">TNF-RII</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">extracellular vesicles</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37809067</ArticleId><ArticleId IdType="pmc">PMC10556683</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1259007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berhan A, Bayleyegn B, Getaneh Z. Hiv/Aids associated lymphoma: review. Blood Lymphat Cancer (2022) 12:31&#x2013;45. doi:&#xa0;10.2147/BLCTT.S361320</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/BLCTT.S361320</ArticleId><ArticleId IdType="pmc">PMC9063794</ArticleId><ArticleId IdType="pubmed">35517869</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen EC, Hussain SK, Magpantay L, Jacobson LP, Detels R, Rabkin CS, et al. . B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic aids-associated non-hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev (2011) 20(7):1303&#x2013;14. doi:&#xa0;10.1158/1055-9965.EPI-11-0037</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-11-0037</ArticleId><ArticleId IdType="pmc">PMC3132317</ArticleId><ArticleId IdType="pubmed">21527584</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll V, Garzino-Demo A. Hiv-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog Dis (2015) 73(7):1&#x2013;7. doi:&#xa0;10.1093/femspd/ftv044</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femspd/ftv044</ArticleId><ArticleId IdType="pmc">PMC4607737</ArticleId><ArticleId IdType="pubmed">26121984</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone A, Gloghini A. Aids-related lymphomas: from pathogenesis to pathology. Br J Haematol (2005) 130(5):662&#x2013;70. doi:&#xa0;10.1111/j.1365-2141.2005.05613.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2005.05613.x</ArticleId><ArticleId IdType="pubmed">16115121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesarman E. Pathology of lymphoma in Hiv. Curr Opin Oncol (2013) 25(5):487&#x2013;94. doi:&#xa0;10.1097/01.cco.0000432525.70099.a4</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.cco.0000432525.70099.a4</ArticleId><ArticleId IdType="pmc">PMC4126602</ArticleId><ArticleId IdType="pubmed">23942293</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel DJ, Rositch AF, Redfield RR, Blattner WA. Hiv-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population. Leuk Lymphoma (2016) 57(2):306&#x2013;12. doi:&#xa0;10.3109/10428194.2015.1055483</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2015.1055483</ArticleId><ArticleId IdType="pubmed">26025299</ArticleId></ArticleIdList></Reference><Reference><Citation>Epeldegui M, Martinez-Maza O. Immune activation: contribution to aids-associated non-hodgkin lymphoma. For Immunopathol Dis Therap (2015) 6(1-2):79&#x2013;90. doi:&#xa0;10.1615/ForumImmunDisTher.2016014177</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/ForumImmunDisTher.2016014177</ArticleId><ArticleId IdType="pmc">PMC5502768</ArticleId><ArticleId IdType="pubmed">28702272</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez LE, Lensing S, Chang D, Magpantay LI, Mitsuyasu R, Ambinder RF, et al. . Immune activation and microbial translocation as prognostic biomarkers for aids-related non-hodgkin lymphoma in the Amc-034 study. Clin Cancer Res (2021) 27(16):4642&#x2013;51. doi:&#xa0;10.1158/1078-0432.CCR-20-4167</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-4167</ArticleId><ArticleId IdType="pmc">PMC8364886</ArticleId><ArticleId IdType="pubmed">34131000</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Maza O, Widney D, van der Meijden M, Knox R, Echeverri A, Breen EC, et al. . Immune dysfunction and the pathogenesis of aids-associated non-Hodgkin's lymphoma. Mem Inst Oswaldo Cruz (1998) 93(3):373&#x2013;81. doi:&#xa0;10.1590/s0074-02761998000300019</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0074-02761998000300019</ArticleId><ArticleId IdType="pubmed">9698872</ArticleId></ArticleIdList></Reference><Reference><Citation>Epeldegui M, Magpantay L, Guo Y, Halec G, Cumberland WG, Yen PK, et al. . A prospective study of serum microbial translocation biomarkers and risk of aids-related non-Hodgkin lymphoma. AIDS (2018) 32(7):945&#x2013;54. doi:&#xa0;10.1097/QAD.0000000000001771</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001771</ArticleId><ArticleId IdType="pmc">PMC5869109</ArticleId><ArticleId IdType="pubmed">29424776</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin J. Cell biology: the ins and outs of exosomes. Science (2005) 308(5730):1862&#x2013;3. doi:&#xa0;10.1126/science.308.5730.1862</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.308.5730.1862</ArticleId><ArticleId IdType="pubmed">15976285</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyer F, Baur A. Biogenesis and functions of exosomes and extracellular vesicles. Methods Mol Biol (2016) 1448:201&#x2013;16. doi:&#xa0;10.1007/978-1-4939-3753-0_15</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3753-0_15</ArticleId><ArticleId IdType="pubmed">27317183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zhang R, Chen G. Exosome and secretion: action on? Adv Exp Med Biol (2020) 1248:455&#x2013;83. doi:&#xa0;10.1007/978-981-15-3266-5_19</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-15-3266-5_19</ArticleId><ArticleId IdType="pubmed">32185722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Ramirez VV, Gonzalez-Sanchez HM, Lucio-Garcia C. Exosomes: from biology to immunotherapy in infectious diseases. Infect Dis (Lond) (2023) 55(2):79&#x2013;107. doi:&#xa0;10.1080/23744235.2022.2149852</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2022.2149852</ArticleId><ArticleId IdType="pubmed">36562253</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. Proteomics (2008) 8(19):4083&#x2013;99. doi:&#xa0;10.1002/pmic.200800109</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200800109</ArticleId><ArticleId IdType="pubmed">18780348</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics (2009) 6(3):267&#x2013;83. doi:&#xa0;10.1586/epr.09.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/epr.09.17</ArticleId><ArticleId IdType="pubmed">19489699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell (2023) 186(8):1610&#x2013;26. doi:&#xa0;10.1016/j.cell.2023.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.03.010</ArticleId><ArticleId IdType="pmc">PMC10484374</ArticleId><ArticleId IdType="pubmed">37059067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou K, Guo S, Li F, Sun Q, Liang G. Exosomal pd-L1: new insights into tumor immune escape mechanisms and therapeutic strategies. Front Cell Dev Biol (2020) 8:569219. doi:&#xa0;10.3389/fcell.2020.569219</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.569219</ArticleId><ArticleId IdType="pmc">PMC7593554</ArticleId><ArticleId IdType="pubmed">33178688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 14(8):561&#x2013;84. doi:&#xa0;10.1038/nrd4591</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4591</ArticleId><ArticleId IdType="pubmed">26228759</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaccio C, Chiozzini C, Columba-Cabezas S, Manfredi F, Affabris E, Baur A, et al. . Exosomes from human immunodeficiency virus type 1 (Hiv-1)-infected cells license quiescent Cd4+ T lymphocytes to replicate Hiv-1 through a Nef- and adam17-dependent mechanism. J Virol (2014) 88(19):11529&#x2013;39. doi:&#xa0;10.1128/JVI.01712-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01712-14</ArticleId><ArticleId IdType="pmc">PMC4178784</ArticleId><ArticleId IdType="pubmed">25056899</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaccio C, Anticoli S, Manfredi F, Chiozzini C, Olivetta E, Federico M. Latent hiv-1 is activated by exosomes from cells infected with either replication-competent or defective Hiv-1. Retrovirology (2015) 12:87. doi:&#xa0;10.1186/s12977-015-0216-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12977-015-0216-y</ArticleId><ArticleId IdType="pmc">PMC4623921</ArticleId><ArticleId IdType="pubmed">26502902</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Li C, Li R, Chen H, Chen D, Li W. Exosomes in Hiv infection. Curr Opin HIV AIDS (2021) 16(5):262&#x2013;70. doi:&#xa0;10.1097/COH.0000000000000694</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0000000000000694</ArticleId><ArticleId IdType="pmc">PMC8373450</ArticleId><ArticleId IdType="pubmed">34321416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampey GC, Saifuddin M, Schwab A, Barclay R, Punya S, Chung MC, et al. . Exosomes from Hiv-1-infected cells stimulate production of pro-inflammatory cytokines through trans-activating response (Tar) Rna. J Biol Chem (2016) 291(3):1251&#x2013;66. doi:&#xa0;10.1074/jbc.M115.662171</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.662171</ArticleId><ArticleId IdType="pmc">PMC4714213</ArticleId><ArticleId IdType="pubmed">26553869</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Jaular L, Nevo N, Schessner JP, Tkach M, Jouve M, Dingli F, et al. . Unbiased proteomic profiling of host cell extracellular vesicle composition and dynamics upon Hiv-1 infection. EMBO J (2021) 40(8):e105492. doi:&#xa0;10.15252/embj.2020105492</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020105492</ArticleId><ArticleId IdType="pmc">PMC8047442</ArticleId><ArticleId IdType="pubmed">33709510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhamedova N, Hoang A, Dragoljevic D, Dubrovsky L, Pushkarsky T, Low H, et al. . Exosomes containing Hiv protein nef reorganize lipid rafts potentiating inflammatory response in bystander cells. PLoS Pathog (2019) 15(7):e1007907. doi:&#xa0;10.1371/journal.ppat.1007907</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007907</ArticleId><ArticleId IdType="pmc">PMC6657916</ArticleId><ArticleId IdType="pubmed">31344124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, Cheng Y, et al. . Hiv Nef is secreted in exosomes and triggers apoptosis in bystander Cd4+ T cells. Traffic (2010) 11(1):110&#x2013;22. doi:&#xa0;10.1111/j.1600-0854.2009.01006.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2009.01006.x</ArticleId><ArticleId IdType="pmc">PMC2796297</ArticleId><ArticleId IdType="pubmed">19912576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Feng Z, Yuan G, Emerson CC, Stewart PL, Ye F, et al. . Human immunodeficiency virus-associated exosomes promote Kaposi's sarcoma-associated herpesvirus infection via the epidermal growth factor receptor. J Virol (2020) 94(9):e01782&#x2013;19. doi:&#xa0;10.1128/JVI.01782-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01782-19</ArticleId><ArticleId IdType="pmc">PMC7163124</ArticleId><ArticleId IdType="pubmed">32051269</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MR, Kashanchi F, Jacobson S. Exosomes in viral disease. Neurotherapeutics (2016) 13(3):535&#x2013;46. doi:&#xa0;10.1007/s13311-016-0450-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0450-6</ArticleId><ArticleId IdType="pmc">PMC4965413</ArticleId><ArticleId IdType="pubmed">27324390</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Chi X, Li R, Ouyang J, Chen Y. Hiv-1-infected cell-derived exosomes promote the growth and progression of cervical cancer. Int J Biol Sci (2019) 15(11):2438&#x2013;47. doi:&#xa0;10.7150/ijbs.38146</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.38146</ArticleId><ArticleId IdType="pmc">PMC6775309</ArticleId><ArticleId IdType="pubmed">31595161</ArticleId></ArticleIdList></Reference><Reference><Citation>Madison MN, Okeoma CM. Exosomes: implications in Hiv-1 pathogenesis. Viruses (2015) 7(7):4093&#x2013;118. doi:&#xa0;10.3390/v7072810</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7072810</ArticleId><ArticleId IdType="pmc">PMC4517139</ArticleId><ArticleId IdType="pubmed">26205405</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes M, Teixeira AL, Medeiros R. The opportunistic effect of exosomes on non-Hodgkin lymphoma microenvironment modulation. Crit Rev Oncol Hematol (2019) 144:102825. doi:&#xa0;10.1016/j.critrevonc.2019.102825</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2019.102825</ArticleId><ArticleId IdType="pubmed">31734546</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalife J, Sanchez JF, Pichiorri F. Extracellular vesicles in hematological Malignancies: from biomarkers to therapeutic tools. Diagnostics (Basel) (2020) 10(12):1065. doi:&#xa0;10.3390/diagnostics10121065</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10121065</ArticleId><ArticleId IdType="pmc">PMC7763630</ArticleId><ArticleId IdType="pubmed">33316884</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloudizargari M, Hekmatirad S, Mofarahe ZS, Asghari MH. Exosomal microrna panels as biomarkers for hematological Malignancies. Curr Probl Cancer (2021) 45(5):100726. doi:&#xa0;10.1016/j.currproblcancer.2021.100726</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.currproblcancer.2021.100726</ArticleId><ArticleId IdType="pubmed">33752898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofori K, Bhagat G, Rai AJ. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: current state of the art and unmet clinical needs. Br J Clin Pharmacol (2021) 87(2):284&#x2013;94. doi:&#xa0;10.1111/bcp.14611</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14611</ArticleId><ArticleId IdType="pubmed">33080045</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez LE, Lensing S, Chang D, Magpantay LI, Mitsuyasu R, Ambinder RF, et al. . Plasma extracellular vesicles bearing Pd-L1, Cd40, Cd40l or Tnf-Rii Are significantly reduced after treatment of aids-nhl. Sci Rep (2022) 12(1):9185. doi:&#xa0;10.1038/s41598-022-13101-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13101-8</ArticleId><ArticleId IdType="pmc">PMC9163074</ArticleId><ArticleId IdType="pubmed">35655072</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza G, Bhondoekhan F, Benning L, Margolick JB, Adedimeji AA, Adimora AA, et al. . Characteristics of the Macs/Wihs combined cohort study: opportunities for research on aging with Hiv in the longest us observational study of Hiv. Am J Epidemiol (2021) 190(8):1457&#x2013;75. doi:&#xa0;10.1093/aje/kwab050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwab050</ArticleId><ArticleId IdType="pmc">PMC8484936</ArticleId><ArticleId IdType="pubmed">33675224</ArticleId></ArticleIdList></Reference><Reference><Citation>Detels R, Jacobson L, Margolick J, Martinez-Maza O, Munoz A, Phair J, et al. . The multicenter aids cohort study, 1983 to. Public Health (2012) 126(3):196&#x2013;8. doi:&#xa0;10.1016/j.puhe.2011.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2011.11.013</ArticleId><ArticleId IdType="pmc">PMC3324261</ArticleId><ArticleId IdType="pubmed">22206985</ArticleId></ArticleIdList></Reference><Reference><Citation>Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, et al. . Circulating levels of Tnf receptor ii are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res (2012) 18(13):3637&#x2013;47. doi:&#xa0;10.1158/1078-0432.CCR-11-3299</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-11-3299</ArticleId><ArticleId IdType="pubmed">22573350</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Kinoshita T, Suzuki S, Nagasaka T, Hatano S, Murate T, et al. . Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (1998) 29(1-2):71&#x2013;9. doi:&#xa0;10.3109/10428199809058383</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428199809058383</ArticleId><ArticleId IdType="pubmed">9638977</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu-Monette ZY, Zhou J, Young KH. Pd-1 expression and clinical Pd-1 blockade in B-cell lymphomas. Blood (2018) 131(1):68&#x2013;83. doi:&#xa0;10.1182/blood-2017-07-740993</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-07-740993</ArticleId><ArticleId IdType="pmc">PMC5755041</ArticleId><ArticleId IdType="pubmed">29118007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. . Exosomal pd-L1 contributes to immunosuppression and is associated with anti-pd-1 response. Nature (2018) 560(7718):382&#x2013;6. doi:&#xa0;10.1038/s41586-018-0392-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0392-8</ArticleId><ArticleId IdType="pmc">PMC6095740</ArticleId><ArticleId IdType="pubmed">30089911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Li J, Zhang R, Zhang Y, Wang X, Leung EL, et al. . Suppression of pd-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting orai1 calcium channels. J Extracell Vesicles (2022) 11(12):e12279. doi:&#xa0;10.1002/jev2.12279</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jev2.12279</ArticleId><ArticleId IdType="pmc">PMC9732629</ArticleId><ArticleId IdType="pubmed">36482876</ArticleId></ArticleIdList></Reference><Reference><Citation>Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. . Suppression of exosomal Pd-L1 induces systemic anti-tumor immunity and memory. Cell (2019) 177(2):414&#x2013;27.e13. doi:&#xa0;10.1016/j.cell.2019.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.02.016</ArticleId><ArticleId IdType="pmc">PMC6499401</ArticleId><ArticleId IdType="pubmed">30951669</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasihashemi SZ, Rezazadeh Gavgani E, Majidazar R, Seraji P, Oladghaffari M, Kazemi T, et al. . Tumor-derived exosomal pd-L1 in progression of cancer and immunotherapy. J Cell Physiol (2022) 237(3):1648&#x2013;60. doi:&#xa0;10.1002/jcp.30645</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30645</ArticleId><ArticleId IdType="pubmed">34825383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, et al. . Immune evasion mediated by pd-L1 on glioblastoma-derived extracellular vesicles. Sci Adv (2018) 4(3):eaar2766. doi:&#xa0;10.1126/sciadv.aar2766</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar2766</ArticleId><ArticleId IdType="pmc">PMC5842038</ArticleId><ArticleId IdType="pubmed">29532035</ArticleId></ArticleIdList></Reference><Reference><Citation>Epeldegui M, Conti DV, Guo Y, Cozen W, Penichet ML, Martinez-Maza O. Elevated numbers of pd-L1 expressing B cells are associated with the development of Aids-Nhl. Sci Rep (2019) 9(1):9371. doi:&#xa0;10.1038/s41598-019-45479-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-45479-3</ArticleId><ArticleId IdType="pmc">PMC6599055</ArticleId><ArticleId IdType="pubmed">31253857</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of Cd40/Cd40l engagement in the immune system. Immunol Rev (2009) 229(1):152&#x2013;72. doi:&#xa0;10.1111/j.1600-065X.2009.00782.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2009.00782.x</ArticleId><ArticleId IdType="pmc">PMC3826168</ArticleId><ArticleId IdType="pubmed">19426221</ArticleId></ArticleIdList></Reference><Reference><Citation>Berberich I, Shu GL, Clark EA. Cross-linking Cd40 on B cells rapidly activates nuclear factor-kappa B. J Immunol (1994) 153(10):4357&#x2013;66. doi:&#xa0;10.4049/jimmunol.153.10.4357</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.153.10.4357</ArticleId><ArticleId IdType="pubmed">7525701</ArticleId></ArticleIdList></Reference><Reference><Citation>Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ, et al. . Cd40 regulates the processing of Nf-Kappab2 P100 to P52. EMBO J (2002) 21(20):5375&#x2013;85. doi:&#xa0;10.1093/emboj/cdf542</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdf542</ArticleId><ArticleId IdType="pmc">PMC129074</ArticleId><ArticleId IdType="pubmed">12374738</ArticleId></ArticleIdList></Reference><Reference><Citation>Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, et al. . Constitutive Cd40 signaling in B cells selectively activates the noncanonical Nf-Kappab pathway and promotes lymphomagenesis. J Exp Med (2008) 205(6):1317&#x2013;29. doi:&#xa0;10.1084/jem.20080238</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20080238</ArticleId><ArticleId IdType="pmc">PMC2413030</ArticleId><ArticleId IdType="pubmed">18490492</ArticleId></ArticleIdList></Reference><Reference><Citation>Song G, Ni H, Zou L, Wang S, Tian F, Liu H, et al. . Expression of cd40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-chop (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). Onco Targets Ther (2016) 9:3799&#x2013;805. doi:&#xa0;10.2147/OTT.S96992</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S96992</ArticleId><ArticleId IdType="pmc">PMC4922817</ArticleId><ArticleId IdType="pubmed">27382316</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 9(5):361&#x2013;71. doi:&#xa0;10.1038/nrc2628</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2628</ArticleId><ArticleId IdType="pubmed">19343034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ham B, Fernandez MC, D'Costa Z, Brodt P. The diverse roles of the tnf axis in cancer progression and metastasis. Trends Cancer Res (2016) 11(1):1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138060</ArticleId><ArticleId IdType="pubmed">27928197</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Yoshimatsu G, Faustman DL. The roles of Tnfr2 signaling in cancer cells and the tumor microenvironment and the potency of Tnfr2 targeted therapy. Cells (2022) 11(12):1952. doi:&#xa0;10.3390/cells11121952</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11121952</ArticleId><ArticleId IdType="pmc">PMC9222015</ArticleId><ArticleId IdType="pubmed">35741080</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Islam MS, Hu Y, Chen X. Tnfr2: role in cancer immunology and immunotherapy. Immunotargets Ther (2021) 10:103&#x2013;22. doi:&#xa0;10.2147/ITT.S255224</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ITT.S255224</ArticleId><ArticleId IdType="pmc">PMC8071081</ArticleId><ArticleId IdType="pubmed">33907692</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose-John S. Interleukin-6 signalling in health and disease. F1000Res (2020) 9:F1000 Faculty Rev&#x2013;1013. doi:&#xa0;10.12688/f1000research.26058.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.26058.1</ArticleId><ArticleId IdType="pmc">PMC7443778</ArticleId><ArticleId IdType="pubmed">32864098</ArticleId></ArticleIdList></Reference><Reference><Citation>Epeldegui M, Lee JY, Martinez AC, Widney DP, Magpantay LI, Regidor D, et al. . Predictive value of cytokines and immune activation biomarkers in aids-related non-Hodgkin lymphoma treated with rituximab plus infusional Epoch (Amc-034 trial). Clin Cancer Res (2016) 22(2):328&#x2013;36. doi:&#xa0;10.1158/1078-0432.CCR-14-0466</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0466</ArticleId><ArticleId IdType="pmc">PMC4715998</ArticleId><ArticleId IdType="pubmed">26384320</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher N, Meyer D, Mauermann A, von der Heyde J, Wolf J, Schwarz J, et al. . Shedding of endogenous interleukin-6 receptor (Il-6r) is governed by a disintegrin and metalloproteinase (Adam) proteases while a full-length il-6r isoform localizes to circulating microvesicles. J Biol Chem (2015) 290(43):26059&#x2013;71. doi:&#xa0;10.1074/jbc.M115.649509</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.649509</ArticleId><ArticleId IdType="pmc">PMC4646259</ArticleId><ArticleId IdType="pubmed">26359498</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold P, Luckstadt W, Li W, Boll I, Lokau J, Garbers C, et al. . Joint reconstituted signaling of the il-6 receptor via extracellular vesicles. Cells (2020) 9(5):1307. doi:&#xa0;10.3390/cells9051307</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051307</ArticleId><ArticleId IdType="pmc">PMC7291149</ArticleId><ArticleId IdType="pubmed">32456348</ArticleId></ArticleIdList></Reference><Reference><Citation>
Satcher Johnson A, Song R, Baker AD, Gant Z, Wu B, Reynolds S, et al. . Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2017&#x2013;2021. HIV Surveillance Supplemental Report, 2023; 28 (No.3). Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention;  (2023). Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (Accessed July 2023).</Citation></Reference><Reference><Citation>
Hohe C, Hu V, Kim A, Kim G, Ma Y, Naghdi A, et al. . Division of HIV and STD Programs, Department of Public Health, County of Los Angeles. HIV Surveillance Annual Report, 2021. ;  (2022). Available at: http://publichealth.lacounty.gov/dhsp/Reports/HIV/2021AnnualHIVSurveillanceReport.pdf (Accessed July 2023).</Citation></Reference><Reference><Citation>Carvalho AS, Baeta H, Henriques AFA, Ejtehadifar M, Tranfield EM, Sousa AL, et al. . Proteomic landscape of extracellular vesicles for diffuse large B-cell lymphoma subtyping. Int J Mol Sci (2021) 22(20):11004. doi:&#xa0;10.3390/ijms222011004</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011004</ArticleId><ArticleId IdType="pmc">PMC8536203</ArticleId><ArticleId IdType="pubmed">34681663</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Cai Y, Liu X, Ji Y, Zhang C, Wang L, et al. . Single-exosome profiling identifies Itgb3+ and Itgam+ Exosome subpopulations as promising early diagnostic biomarkers and therapeutic targets for colorectal cancer. Res (Wash D C) (2023) 6:41. doi:&#xa0;10.34133/research.0041</Citation><ArticleIdList><ArticleId IdType="doi">10.34133/research.0041</ArticleId><ArticleId IdType="pmc">PMC10076010</ArticleId><ArticleId IdType="pubmed">37040507</ArticleId></ArticleIdList></Reference><Reference><Citation>Larssen P, Wik L, Czarnewski P, Eldh M, Lof L, Ronquist KG, et al. . Tracing cellular origin of human exosomes using multiplex proximity extension assays. Mol Cell Proteomics (2017) 16(8):1547. doi:&#xa0;10.1074/mcp.A116.064725</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.A116.064725</ArticleId><ArticleId IdType="pmc">PMC5546203</ArticleId><ArticleId IdType="pubmed">28765260</ArticleId></ArticleIdList></Reference><Reference><Citation>Manouchehri Doulabi E, Fredolini C, Gallini R, Lof L, Shen Q, Ikebuchi R, et al. . Surface protein profiling of prostate-derived extracellular vesicles by mass spectrometry and proximity assays. Commun Biol (2022) 5(1):1402. doi:&#xa0;10.1038/s42003-022-04349-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-04349-x</ArticleId><ArticleId IdType="pmc">PMC9780212</ArticleId><ArticleId IdType="pubmed">36550367</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro-Tableros V, Gomez Y, Camussi G, Brizzi MF. Extracellular vesicles: new players in lymphomas. Int J Mol Sci (2018) 20(1):41. doi:&#xa0;10.3390/ijms20010041</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20010041</ArticleId><ArticleId IdType="pmc">PMC6337615</ArticleId><ArticleId IdType="pubmed">30583481</ArticleId></ArticleIdList></Reference><Reference><Citation>Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal pdl1 in tumour immune evasion. Nat Rev Immunol (2020) 20(4):209&#x2013;15. doi:&#xa0;10.1038/s41577-019-0264-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0264-y</ArticleId><ArticleId IdType="pubmed">31965064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Shi Y. Exosomes derived from immune cells: the new role of tumor immune microenvironment and tumor therapy. Int J Nanomedicine (2022) 17:6527&#x2013;50. doi:&#xa0;10.2147/IJN.S388604</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S388604</ArticleId><ArticleId IdType="pmc">PMC9790146</ArticleId><ArticleId IdType="pubmed">36575698</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of Pd-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res (2018) 24(4):896&#x2013;905. doi:&#xa0;10.1158/1078-0432.CCR-17-2664</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2664</ArticleId><ArticleId IdType="pmc">PMC6126905</ArticleId><ArticleId IdType="pubmed">29233903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Xu Z, Zheng L, Zhang L, You Q, Sun J. Multimodal detection of pd-L1: reasonable biomarkers for immune checkpoint inhibitor. Am J Cancer Res (2018) 8(9):1689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176186</ArticleId><ArticleId IdType="pubmed">30323963</ArticleId></ArticleIdList></Reference><Reference><Citation>Epeldegui M, Hussain SK. The role of microbial translocation and immune activation in aids-associated non-Hodgkin lymphoma pathogenesis: what have&#xa0;we&#xa0;learned? Crit Rev Immunol (2020) 40(1):41&#x2013;51. doi:&#xa0;10.1615/CritRevImmunol.2020033319</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevImmunol.2020033319</ArticleId><ArticleId IdType="pmc">PMC7241309</ArticleId><ArticleId IdType="pubmed">32421978</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>